S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:MDWD

MediWound (MDWD) Stock Price, News & Analysis

$15.10
-0.46 (-2.96%)
(As of 03/27/2024 ET)
Today's Range
$15.06
$15.74
50-Day Range
$11.25
$17.11
52-Week Range
$7.10
$17.25
Volume
58,765 shs
Average Volume
98,745 shs
Market Capitalization
$143.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

MediWound MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
111.9% Upside
$32.00 Price Target
Short Interest
Healthy
1.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of MediWound in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.84) to ($1.58) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.08 out of 5 stars

Medical Sector

585th out of 939 stocks

Medicinals & Botanicals Industry

4th out of 11 stocks

MDWD stock logo

About MediWound Stock (NASDAQ:MDWD)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MDWD Stock Price History

MDWD Stock News Headlines

The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
MediWound's (MDWD) Buy Rating Reaffirmed at HC Wainwright
MediWound (NASDAQ:MDWD) Upgraded by StockNews.com to Hold
CBOE shift unlocks new weekend income strategy
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend.
MediWound: Q4 Earnings Snapshot
MediWound Q4 2023 Earnings Preview
MediWound (MDWD) Set to Announce Earnings on Thursday
MediWound Shares Climb on Positive Data for EscharEx
See More Headlines
Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/21/2023
Today
3/28/2024
Next Earnings (Estimated)
6/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:MDWD
Employees
100
Year Founded
2001

Price Target and Rating

Average Stock Price Target
$32.00
High Stock Price Target
$36.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+111.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-6,720,000.00
Pretax Margin
-34.95%

Debt

Sales & Book Value

Annual Sales
$18.69 million
Book Value
$3.43 per share

Miscellaneous

Free Float
8,619,000
Market Cap
$143.30 million
Optionable
Optionable
Beta
0.94

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Ms. Hani Luxenburg (Age 51)
    Chief Financial Officer
    Comp: $235k
  • Mr. Ofer Gonen B.Sc. (Age 51)
    Chief Executive Officer
    Comp: $485k
  • Dr. Lior Rosenberg M.D. (Age 78)
    Co-Founder
    Comp: $727k
  • Dr. Shmulik Hess Ph.D. (Age 51)
    COO & Chief Commercial Officer
  • Mr. Yaron Meyer Adv. (Age 45)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $240k
  • Mr. Barry J. Wolfenson (Age 57)
    Executive Vice President of Strategy & Corporate Development
  • Dr. Ety Klinger MBA (Age 62)
    Ph.D., Chief Research & Development Officer
    Comp: $393k
  • Dr. Robert J. Snyder CWS (Age 74)
    D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer

MDWD Stock Analysis - Frequently Asked Questions

Should I buy or sell MediWound stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings
or view top-rated stocks.

What is MediWound's stock price target for 2024?

2 brokers have issued 12 month target prices for MediWound's stock. Their MDWD share price targets range from $28.00 to $36.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 111.9% from the stock's current price.
View analysts price targets for MDWD
or view top-rated stocks among Wall Street analysts.

How have MDWD shares performed in 2024?

MediWound's stock was trading at $10.17 at the start of the year. Since then, MDWD shares have increased by 48.5% and is now trading at $15.10.
View the best growth stocks for 2024 here
.

Are investors shorting MediWound?

MediWound saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 153,300 shares, an increase of 99.9% from the February 29th total of 76,700 shares. Based on an average trading volume of 58,700 shares, the days-to-cover ratio is presently 2.6 days. Approximately 1.6% of the company's shares are sold short.
View MediWound's Short Interest
.

When is MediWound's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024.
View our MDWD earnings forecast
.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) released its quarterly earnings data on Tuesday, November, 21st. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.21. The biopharmaceutical company earned $4.78 million during the quarter, compared to analysts' expectations of $4.73 million. MediWound had a negative trailing twelve-month return on equity of 20.22% and a negative net margin of 35.94%. During the same quarter in the previous year, the business earned ($0.91) earnings per share.

When did MediWound's stock split?

Shares of MediWound reverse split before market open on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

Who are MediWound's major shareholders?

MediWound's stock is owned by many different institutional and retail investors. Top institutional shareholders include Yelin Lapidot Holdings Management Ltd. (1.36%), Sargent Investment Group LLC (1.19%), Silverberg Bernstein Capital Management LLC (0.86%), Sphera Funds Management LTD. (0.53%), Essex Investment Management Co. LLC (0.42%) and Citadel Advisors LLC (0.18%).

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDWD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners